RxDoctor Payments Data

David Arehart, MD

Interventional Pain Medicine · Hopkinsville, KYNPI 1306802061

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 33.1% of the total. Reporting peaked in 2019 at $228 and has fallen 69.8% since, to $69 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in KY, where the typical reported total is $3,169.

$651in general payments, 2019–2025

Across 35 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$216
  • Daiichi Sankyo Inc.$108
  • Boston Scientific$77
  • Abbott$68
  • Takeda Pharmaceuticals U.S.A., Inc.$27
  • Biodelivery Sciences International, Inc.$25
  • plus $130 from 7 others

What the payments were for

  • Food & beverage$651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$651 in reported general payments places this provider in the 15th percentile of 55 interventional pain medicine providers in Kentucky.

See all interventional pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$276,711
Medicare patients
213
Services billed
2,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate157$127,695
BelbucaBuprenorphine Hcl70$75,391
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,223$68,231
LinzessLinaclotide110$58,180
Fentanyl333$44,968
Buprenorphine93$32,221
OxycontinOxycodone Hcl48$29,129
MovantikNaloxegol Oxalate48$19,356
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen633$18,375
Morphine Sulfate ErMorphine Sulfate762$17,640
Gabapentin1,078$16,831
Naloxone Hcl166$10,418
Pregabalin425$6,694
Lubiprostone33$4,947
Tizanidine Hcl281$2,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$216$203,087227 claims
Redhill Biopharma Inc.Movantik$25$19,35648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 55 interventional pain medicine providers in Kentucky.

Other interventional pain medicine in Hopkinsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →